This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's financial condition, results of operations, as well as statements regarding the Company's plans and expectations for operations including its planned wind down of operations in Europe; the Company's plans and expectations for the timing of BLA submissions; the potential for any licensing or partnership transactions; and the company's expectations for the commercialization of ABECMA through the BMS collaboration; the timing, leadership, structure, including the division of assets among bluebird bio and 2seventy bio, and the impact of a separation; as well as the company's intention to provide further updates on the separation and the related financing strategies for bluebird bio and 2seventy.